Press releases
2018. 11. 22
SK bioscience announced that the company has won the award from the Minister of Food and Drug Safety(KMFDS) for its contributions to the domestic biopharmaceutical industry at the ´2018 Medical Korea Award´ ceremony held at the Grand Intercontinental Parnas Hotel, Seoul, Republic of Korea.
KMFDS held the 11th annual MEDICAL KOREA event this year to choose and award to
top pharmaceutical, and medical device companies, hospitals, medical clinics,
etc., which have led the advancement of the entire biopharmaceutical industry in
Korea this year.
SK bioscience gained recognition for raising the level of R&D technology of
the domestic vaccine industry by producing self-developed vaccines, including the
world´s first tetravalent cell culture flu vaccine, ‘SKYCellflu® Quadrivalent´, ‘SKYZoster®´,’ a zoster
vaccine which raised the domestic self-sufficiency to 50%, and the Korea’s second varicella vaccine ‘SKYVaricella®´.’
SK bioscience received the annual award for 4 years in a row ever since SKYCellflu was
awarded the Grand Prize in the Medical Korea Awards vaccine category in 2015,
before it was split off from parent company, SK chemicals.
SKYCellflu Quadrivalent is a cell culture-based influenza vaccine
that can prevent four types of influenza viruses once administered. Cell
culture-based production technology is fast and efficient in production by utilizing
animal cells instead of a fertilized egg. In addition, since the production
period is only one-half that of a fertilized egg and without using any antibiotics
or preservatives in the manufacturing process, it can respond more quickly to
emergency situations.
Based on these strengths, SK bioscience transferred its cell-cultivated production
technology to global vaccine company last February.
Jaeyong Ahn, CEO of SK bioscience said, said, "The outstanding achievement
we made in domestic and overseas markets have returned as meaningful awards. We
will become a global innovator of vaccine industry and a leader in the global
market beyond Korea through continuous R&D investment."